Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 11/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203246 | 0.82 | GRIN2B (0.47) | KIF11 | |
| SCHEMBL13249281 | 0.81 | MEP1B (0.44) | CETPDAO | |
| SCHEMBL27266886 | 0.80 | KDM4E (0.45) | — | |
| SCHEMBL5973660 | 0.79 | MAOB (0.57) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL4176842 | 0.78 | MAOB (0.56) | CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL29076665 | 0.78 | MAOB (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL1044620 | 0.76 | CHRM2 (0.57) | MAPK14CETPCHRM2CHRM1CHRM3 | |
| SCHEMBL13249283 | 0.76 | BCHE (0.47) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27484241 | 0.76 | FDFT1 (0.44) | CETP | |
| SCHEMBL5009648 | 0.76 | DAO (0.55) | MAPK14CETPCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179137-A1 | PYRIDONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179137-A1 | PYRIDONE COMPOUND | PTGER4, P2RY4, PTGER1 | MAPK14 1636/4885CETP 3420/4885CHRM2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.